P
roteogiycans are a group of complex and diverse macromolecules that are present in all tissues and synthesized by all cells. These macromolecules are found in four locations: 1) throughout the extracellular matrix (ECM), 2) associated with specialized structures of the ECM such as basement membrane and basal laminae, 3) part of, or associated with, the plasma membrane of cells, and 4) in intracellular structures such as secretory storage granules and synaptic vesicles. Proteogiycans contain core proteins to which one or more glycosaminoglycans are covalently attached through O-glycosidic linkage to serine residues in the protein core. Usually one type of glycosaminoglycan predominates on a single core protein, giving rise to four main families: chondroitin sulfate proteoglycan (CSPG), dermatan sulfate proteoglycan (DSPG), heparan sulfate proteoglycan (HSPG), and keratan sulfate proteoglycan (KSPG). In addition to glycosaminoglycans, both N-and O-linked oligosaccharides may be covalently attached to the protein core. Figure 1 shows a schematic representation of the basic structure of a typical proteoglycan.
The diversity of proteogiycans largely derives from the number of different protein cores within specific proteoglycan families and from the polydispersity produced by a large variety of posttranslational modifications required to construct the final molecule. Figure 2 gives examples of the diversity and structure of typical proteogiycans found in tissues such as blood vessels. No doubt this structural diversity contributes to a variety of different biological functions attributed to these molecules. Recent reviews consider the structural characteristics of proteogiycans in detail. 1 ' 2 Although proteogiycans constitute a minor component of vascular tissue (2% to 5% by dry weight) as compared to cartilage (50% by dry weight), a number of studies over the years have demonstrated that these macromolecules are of enormous importance in influencing such arterial properties as viscoelasticity, permeability, lipid metabolism, hemostasis, and thrombosis. 34 ' 6 To date, three major families of proteogiycans have been identified in blood vessels and synthesized by vascular cells. These families include proteogiycans enriched in chondroitin sulfate, dermatan sulfate, and heparan sulfate. Histochemical, 8 -11 immunocytochemical, 12 -17 and biochemical 18 data indicate that these different families are distributed differently in the arterial wall ( Figures 3, 4 , and 5). For example, a large CSPG (-1.2 x 10 6 M,) is present principally in the interstitial matrix of the ECM.S.AIO.H.U.IS w hj| e a small DSPG (~120 to 180 kd M,) is confined to the periphery of collagen fibrils 101114 ( Figures 5B and 5C ). Heparan sulfate proteogiycans appear to be present in arterial basement membranes 1317 ( Figure 5A ) and closely associated with elastic fibers. Cell culture studies of vascular cells also have revealed that certain classes of proteogiycans are hydrophobic and may be associated with plasma membranes. 1920 ' 21 The fact that proteogiycans are found in different locations in the arterial wall indicates probable differences in the function of each family of vascular proteogiycans.
A hallmark of early and late atherosclerosis is the accumulation of proteogiycans in the intimal lesions (Figures 3 and 4) . 3 ' 4 ' 5 ' 1622 Such accumulation may predis- pose the arterial wall to lipid accumulation, calcification, and thrombosis by virtue of the ability of proteoglycans to interact with component molecules involved in these processes. In addition, enrichment in proteoglycans characterizes vascular conditions such as aneurysms associated with Marfan Syndrome, 23 veno-occlusive disease occurring in arteriovenous fistulas, 24 and cerebral amyloid angiopathy, a condition affecting cerebral vessels in Alzheimer's disease. 25 It is of interest that an antibody raised against an arterial CSPG has been used effectively to "image" plaques in developing atherosclerotic arteries in experimental animals. 26 These studies collectively indicate the involvement of proteoglycans in cardiovascular diseases. However, it is still not clear why proteoglycans accumulate and what specific effects these molecules have on events associated with the pathogenesis of these diseases. This review focuses on these two questions with emphasis on recent developments in the field of arterial proteoglycans, since studies prior to 1980 have already been reviewed. 
Vascular Cell Proteoglycans Endothellal Cells
Vascular endothelial cells synthesize and secrete both heparan sulfate and dermatan sulfate containing proteo- 
glycans.
19 -27 -38 These molecules differ In size and in ability to interact with other molecules. For example, there are a number of size classes of HSPG present in endothelial cultures. One form is hydrodynamically large (-400 kd) and sediments in cesium chloride at low buoyant density. 28 - 31 It appears that the larger species of HSPG exists as disulfide bonded aggregates, 3031 linked either to itself or to other matrix components, as has been demonstrated for HSPG in a mouse tumor basement membrane.
3 *- 43 In addition, a HSPG (-250 to 400 kd) from cultured vascular endothelial cells that exhibits hydrophobic properties interacts specifically with antithrombin |||19.36,37.38 a n c j > therefore, is thought to play a critical role in providing a nonthrombogenic surface for the vascular endothelium (see also Hemostasis section).
Structural differences among the subclasses of endothelial derived HSPGs may arise in part from the synthesis of unique HSPGs on cores that are distinct products of separate genes. For example, Stow and coworkers 4445 have shown that antibodies raised against a putative hepatocyte plasma membrane HSPG failed to stain glomerular basement membrane, staining only the surfaces of kidney epithelia and endothelia, while the reverse was true for an antibody raised against HSPG from basement membrane. The most recent study by this group 46 has shown that certain cell types in culture synthesize two forms of HSPG, one that possesses hydrophobic properties consistent with a membrane location and another that is nonhydrophobic and reacts only with the antibasement membrane HSPG antibody. Others have shown similarly that structurally distinct cell surface and basement membrane associated HSPGs found in mouse mammary epithelial cells also are immunologically distinct.
4748
A recent study of the high-and low-density forms of HSPG in the Engebreth-Holm-Swarm (EHS) basement membrane producing tumor indicates that the two forms contain distinctly different core proteins and glycosamincglycan chains. 49 Alternatively, posttranslatjonal or postsecretional processing also may generate some of the multiple HSPG species, either as a mechanism for targeting HSPGs with different functions to different cellular and extracellular compartments or as a result of HSPG turnover. For example, Ledbetter et al. 50 identified a 400 kd precursor protein that was converted to a large, low-density HSPG in the EHS tumor system. Similarly, Klein et al. 51 recently presented evidence that the glomerular basement membrane HSPG (M r =~130 000 to 200 000) 5253 was derived from a larger HSPG precursor (M, -4 0 0 000 to 600 000). Other studies following the secretion, uptake, and intracellular degradation of single HSPG species indicate that several species of HSPG are generated by turnover mechanisms operating in cell culture. 54 Thus, it appears that endothelial cells are the source of a variety of HSPG subclasses. Their origin and specific function(s) await further study.
Vascular endothelial cells also synthesize a family of proteoglycans that contain dermatan sulfate. 16 These proteoglycans contain glycosaminoglycan chains of low iduronic acid content (-10%) when the cells are cultured on plastic, but a higher percentage of iduronic acid when cultured on collagen gels. 32 At least three separate subspecies have been identified. One species appears to be a long-lived (t 1/2 =40 hours) high molecular weight complex consisting of DSPG covalently linked to fibronectin via transglutaminase cross-linking. 55 Two other DSPGs can be distinguished in these cultures (M r =~220 000 and -130 000); these resemble similar subclasses that have been designated as DSPG I and II in cartilage and a variety of other tissues (reviewed in references 56 and 57).
It is now clear that a significant proportion of the proteoglycans synthesized by endothelial cells are deposited as basement membranes. For example, an antibody raised against the large low density HSPG in the EHS tumor immunostains the matrix synthesized by cultured bovine aortic endothelial cells 28 and vascular basement membranes. 1317 The role of proteoglycans as part of this specialized structure appears to be at least twofold. One role is to serve as a structural organizer of the other components of the basement membrane (such as type IV collagen, laminin, entactin, and fibronectin) by virtue of the ability of proteoglycans to interact at specific sites within each of these molecules. 39 - 4258 Another role is to contribute to the selective filtration barrier function of basement membrane by conferring a network of fixed charges to this structure. 59 Alterations in the proteoglycan content of basement membranes severely compromise the functioning of this filtration barrier. 59 - 67 Basement membranes in diabetic tissues have a reduced HSPG content and are undersulfated.
63 " 67 Such alterations are thought to contribute to the increased vascular wall permeability frequently seen in diabetes.
68

Smooth Muscle Cells
Unlike endothelial cells that synthesize predominantly HSPGs, vascular smooth muscle cells synthesize and secrete principally CSPGs and DSPGs with considerably less HSPG 69 -78 ( Figures 6 and 7) . In general, these proteoglycans resemble the bulk of the proteoglycans present in intact arteries. 79 " 85 Chondroitin sulfate proteoglycan is a major arterial proteoglycan. Biochemical and ultrastructural studies of CSPG synthesized by cultured monkey arterial smooth muscle cells indicate that they are hydrodynamically large molecules (M r =~1.2x10 6 ) that consist of a core glycoprotein measuring 220 nm to 320 nm in length (M, -3 9 0 000 to 500 000) to which are attached 15 to 20 chondroitin sulfate (CS) chains with M, -4 0 000 to 60 000 (Figures 2 and 7) . 717277 . 78 In addition, a large number of O-linked oligosaccharides (-300) and a few N-linked oligosaccharides are attached to the CS core protein. 72 A similar size core glycoprotein has been observed from CSPG isolated from bovine aorta after removal of the CS chains by chondroitinase digestion, 83 and the presence of both N-and O-linked oligosaccharides on a large CSPG isolated from human aorta has been confirmed. 86 The large CSPG isolated from blood vessels 788285 and arterial smooth muscle cell cultures 717276 aggregates with hyaluronic acid (HA) and in this respect resembles the major and well-characterized CSPG present in cartilage. 1 Figure 5 . Electron micrographs demonstrating specific locations of various families of aortic proteoglycans. A. Segments of fixed rat aorta were incubated with '"l-anti-HSPG antisera and were labeled with antibody localized to the basement membrane beneath endothelial cells. 13 x8500. Bar=2 /xm. B. Thin sections of rabbit aorta that were lightly "etched" and immunostained with a monoclonal antibody against aortic CSPG and a secondary antibody tagged with immunogold. Immunogold is confined to strands in the interstitial matrix. x25 000. Bar=0.5 ^m . C. Thin section of human superficial artery immunogold stained with antisera against DSPG. Note specific location of gold particles along collagen fibrils. x27 000. Bar=0.5 /nn. aggregate formed in blood vessels is stabilized by at least one accessory link protein.
Immunocytochemical studies reveal that a large CSPG is restricted to the interstitial matrix of arterial smooth muscle cell cultures and blood vessels and is not part of other matrix components such as collagen, elastic fibers, and basal laminae 15 ( Figure 3 ). However, a smaller CSPG that has hydrophobic properties and is immunologically distinct from the large interstitial CSPG is present in nonhuman primate arterial smooth muscle cell cultures and may be associated with the plasma membrane of these cells. 21 A CSPG has been identified on the surface of rat arterial smooth muscle cells, 20 as well as associated with membranes of other cell types. 8990 At present, it is not clear what role these membrane-associated proteoglycans play in the physiology of vascular cells, but they most probably are involved in mechanisms associated with cell adhesion, migration, and proliferation (see next section).
A second population of smaller proteoglycans containing dermatan sulfate also is synthesized by arterial smooth muscle cells. Electron microscopy of purified DSPG from these cells reveals a short core glycoprotein (100 nm) with 1 to 2 glycosaminoglycan side chains of M, -4 0 000 to 60 000 (Figure 2) . 16 The core glycoprotein of this class is -4 5 000 (Figure 7 ). These cells appear to synthesize two types of DSPG. One species is present in the culture medium and contains a low percentage of iduronic acid (<20%). 91 The other class is deposited in the cell layer matrix and contains a much higher percentage of iduronic acid (-50%); it is the predominant proteoglycan deposited when arterial smooth muscle cells are cultured on collagen gels. 91 Two types of DSPG that vary in iduronic acid content also have been found in intact blood ves- sels. 81 •** Unlike CSPG, the DSPGs are closely associated with the periphery of collagen fibrils at regular intervals in blood vessels.
101114 Considerable biochemical and morphological evidence indicates that DSPG is capable of binding to collagen fibrils and influencing collagen fibrillogenesis in some tissues.
92 -9394 A recent study demonstrated that collagen fibril diameter increases from vessel intima to adventitia and is correlated with decreasing proteoglycan concentration. 85 Tissues enriched in collagen, such as advanced atherosclerotic plaques, also are enriched in DSPG (Figure 4) . Dermatan sulfate proteoglycans synthesized by arterial smooth muscle cells resemble similar molecules found in a number of tissues including sclera, tendon, skin, cartilage, 256 and blood vessels. 96 In vitro translation experiments with RNA from arterial smooth muscle cells and an antibody against the small DSPG present in cartilage and skin indicates that the core protein of the arterial smooth muscle cell DSPG is -4 1 kd and is immunologically related to both skin and cartilage DSPG. 97 In addition, recent experiments indicate similar core protein sizes for DSPGs that are synthesized by arterial smooth muscle cells and skin fibroblasts. 98 Interestingly, however, the DSPG synthesized by arterial smooth muscle cells is larger, due to longer glycosaminoglycan chains, and contains less iduronic acid than the DSPG secreted by skin fibroblasts. 64 Both the large (CSPG) and the small (DSPG) proteoglycans synthesized by arterial smooth muscle cells in culture appear to be secreted at similar rates with a T 1/2 of 8 minutes (i.e., transit time from Golgi to the cell surface) (Yeo and Wight, unpublished observations), which is comparable to the secretion kinetics of other proteoglycan secreting cells such as rat ovarian granulosa cells, 99 chondrocytes, and skin fibroblasts. However, it is of interest that these two types of proteoglycans are internalized by arterial smooth muscle cells at different rates, with DSPG exhibiting rapid, high-affinity, and saturable kinetics of uptake, whereas CSPG is taken up more slowly and by a low-affinity endocytic process. 102 These data indicate that the turnover of different families of proteoglycans proceed at different rates.
A third class of proteoglycan synthesized by arterial smooth muscle cells contains heparan sulfate chains. This class represents a minor fraction of the total proteoglycans synthesized by these cells and is usually found in larger amounts in the cell layer matrix (-20%) than in the medium (<5%). The majority of HSPG present in the cell layer elutes as a complex in the void volume of a Sepharose CL-2B column but shifts to an included position of Kav 0.6 when extracted in the presence of detergent. 21 The HS chains are long (M, -4 0 000 to 60 000) and both N-and O-linked oligosaccharides are attached to the protein core. This molecule has an affinity for hydrophobic binding resins and may represent an intercalated plasma membrane form of HSPG. Recent studies have identified a population of HSPGs on the surface of rat arterial smooth muscle cells that gives rise to heparan sulfate chains upon trypsin treatment of the cultures. 20 In addition to the hydrophobic HSPG, arterial smooth muscle cells synthesize a nonhydrophobic HSPG of similar size. 21 At this point, it is not clear how these two forms are related and whether they represent distinctive populations specifically associated with plasma membranes and ECM structures such as basal laminae.
The above studies illustrate that multiple subclasses of proteoglycans exist within each family of arterial proteoglycan. Table 1 presents a tentative list of the various subclasses of arterial smooth muscle cell proteoglycans. It now becomes important to determine whether these subclasses have distinctly different biological functions.
Cell Adhesion
The capacity of endothelial cells to adhere to their connective tissue substrata is critical to the maintenance of normal vascular hemostasis. In fact, temporary detachment of endothelial cells has been postulated as one of the early events in the genesis of atherosclerotic lesions. 103 Experimental removal of endothelial cells leads to marked atherosclerotic development in experimental animals. 103 Thus, it is important to understand those factors involved in endothelial cell adhesion. Proteoglycans have been implicated in the adhesion of a variety of cells to their substratum. 104 - 105 Most cells, including vascular endothelial cells, interact with their substrata in specialized areas of the cell known as focal adhesion sites. 116 - 119 These sites are enriched on the ECM side in attachment proteins, such as fibronectin and heparan sulfate proteoglycans. and on the cytoplasmic side in actin microfilaments. 119 Colocalization of HSPG with cytoskeletal elements such as actin suggests that proteoglycans may influence cell adhesion through association with the cytoskeleton. 111116 Recent studies have shown that the integrity of actin stress filaments is critical for endothelial cell adherence when exposed to shear stress. 118 Although it is not completely certain as to how cell-associated HSPG mediates cellular adhesion, one theory is that proteoglycans may stabilize the adhesion process by interacting with specific proteoglycan binding domains in the attachment protein, such as fibronectin, thus stabilizing the interaction of fibronectin with its cell surface receptor. 116120 It is of interest that removal of HSPG from endothelial cells does not detach cells but does prevent cells from reattaching. 112 Such studies indicate that endothelial cells, like many other cell types, possess multiple adhesion mechanisms. The fact that heparin and heparan sulfate treatment of deposited endothelial-derived extracellular matrix significantly inhibits endothelial cell adhesion 113 supports the hypothesis that proteoglycans may be facilitating attachment by interacting with other adhesion molecules. Late passage endothelial cells that detach more readily than early passage endothelial cells also are characterized by less proteoglycan at their attachment sites. 109 While HSPG appears to promote cell attachment for some cells, other proteoglycans have opposite effects. For example, both CSPG and DSPG inhibit the attachment of a variety of cells to either fibronectin or type I collagen.
56104105106 ' 108110115 These proteoglycans may destabilize focal cellular adhesions, 114 possibly interfering with specific cell binding sites in the adhesive glycoproteins. 120 For example, the proteoglycan may bind to the adhesion protein and sterically interfere with the binding of the protein to its cell surface receptor. Alternatively, the binding of proteoglycan may change the configuration of the protein, causing a decrease in its association constant for the receptor. Evidence for a conformational change upon proteoglycan binding has recently been reported for plasma fibronectin. 121 Thus, it appears that proteoglycans influence adhesion by modulating the activities of the primary molecular components involved in this process.
Proteoglycans also may influence cell-to-cell association. For example, the heparan sulfate chains of HSPG enriched in iduronic acid from postconfluent fibroblasts show selective affinity for cognate heparan sulfate chains. 122 This property may enable membrane forms of HSPG to self-associate and thus have a stabilizing influence on cell-cell association. Growing cells, which should be less adhesive, contain cell-surface HSPG with heparan sulfate chains that show little tendency to self-associate. 123 Proteoglycans also appear to induce the formation of gap junctions in primary liver cultures by stimulating the synthesis of a specific gap junction protein. 124 It remains to be seen whether a similar situation exists for other types of cells such as vascular endothelial and smooth muscle cells.
Cell Migration
The migration of vascular endothelial cells in response to injury or during angiogenesis and of smooth muscle cells during intimal hyperplasia are critical events in vascular wall development and disease. 103 The migration of vascular cells is thought to be highly dependent on their ability to synthesize and secrete certain components of the extracellular matrix. For example, Madri and Stenn 125 have shown that changes occur in the distribution of collagens and laminin during vascular endothelial cell sprouting and migration in vitro and have suggested that continued secretion of collagen is required for effective migration of these cells. Kinsella and Wight 29 have demonstrated that endothelial cells induced to migrate by wounding increase their synthesis of proteoglycan by fourfold and shift from synthesizing a primarily HSPG-rich endothelial matrix to synthesizing a CSPG/DSPG-rich matrix ( Figure 8 ). Autoradiographic evidence revealed that incorporation of proteoglycan precursor ( 35 S-sulfate) was greatest in migrating cells near the wound edge. These results support the concept that proteoglycans participate in the migratory response of cells. A number of recent studies indicate that the migration of neural crest cells is inhibited by the addition of CSPG when added to collagen or fibronectin matrices, suggesting decreased cell-substratum adhesion. 126127128 It is tempting to speculate that the glucuronic acid-rich DSPG synthesized by endothelial cells after wounding 29 is involved in the facilitation of migration by interfering with the cell's adhesive mechanism. Oohira et al. 28 noticed the loss of HSPG in cultures of sprouting (migrating) endothelial cells and Ausprunk et al. 129 presented histochemical evidence suggesting that HSPG is depleted at the tips of growing capillaries. Other factors known to influence angiogenesis, such as interleukins, also exhibit a marked effect on proteoglycan deposition by vascular endothelial cells, 130131 but it is not known whether such factors influence the migration of these cells.
Smooth muscle cell migration from the media to the intima of blood vessels is an important component of the early vascular response to injury and, as such, may play a pivotal role in atherogenesis. 103 Little is known about the factors that control this process. Recent studies by Majack and Clowes 132 have shown that heparin inhibits arterial smooth muscle cell migration in vitro in a dose-dependent and reversible fashion, but hyaluronate and chondroitin or dermatan sulfate do not. Furthermore, this effect was specific for arterial smooth muscle cells, since similar 29 Shaded areas represent proportion of total radioactivity present in the cell layer. B. DEAE-Sephacel ion exchange chromatography of 35 SO 4 -labeled cell layer extracts from confluent ( -) and wounded (-) cultures 48 hours after wounding. Note the large increase in the proportion of radioactivity associated with DSPG containing peak C. treatments had no effect on cultured bovine aortic endothelial cells or Swiss 3T3 cells. In fact, heparin stimulates the migration of bovine capillary endothelial cells. 133 The mechanism for the antimigratory effect of heparin on smooth muscle cells is not yet known.
Such studies indicate that vascular cell migration is accompanied by qualitative and quantitative changes in proteoglycans. It remains to be shown whether such changes regulate this cellular response and if so, how these changes affect the "migratory machinery" of the cell.
Cell Proliferation
Two key events in the development of the atherosclerotic plaque are the proliferation of arterial smooth muscle cells and the deposition of components of the extracellular matrix. An important question is whether these two events are related. Recent studies indicate that quiescent arterial smooth muscle cells increase their synthesis of proteoglycan when stimulated to divide ( Figure 6B ) and this increase occurs principally during the G1 phase of the cell cycle.
7 7 7 8 1 3 4 1 3 5 1 3 6 The activity of several enzymes involved in the synthesis of chondroitin sulfate chains, such as xylosyl transferase, N-acetylgalactosaminyl transferase I, and two sutfotransferases, increase during the prolrferative phase in arterial smooth muscle cell cultures. 136 These results suggest that stimulation may involve, In part, an increased capacity of the cells to synthesize the glycosaminoglycan moiety of the proteoglycans. This increase in synthesis is not restricted to proteoglycans, since other matrix molecules such as collagen and thrombospondin also increase during growth stimulation. 137138 These changes may, in part, account for the initial accumulation of matrix molecules during the prolrferative phase of atherosclerosis. At present, it is not clear whether these synthetic modulations are necessary for proliferation or are a consequence of the proliferative response. It is of interest that growth stimulation of densityarrested Balb 3T3 cells is accompanied by an increase in the capacity of the cells to glycosylate proteins, 139 and interference with this capacity markedly inhibits some cells from progressing through their cell cycle. 140141 Such results suggest that cell cycle progression may rely on the expression of specific glycoproteins and/or proteoglycans.
Proteoglycans also have been implicated in the inhibition of cell proliferation. For example, HSPG derived from postconfluent endothelial and smooth muscle cells inhibits the proliferation of arterial smooth muscle cells, 142 -147 and this inhibitory activity is highly dependent on the presence of a platelet heparitinase in serum. 3738142144 This enzyme generates dodecasaccharide heparan sulfate fragments, 148 -151 which are active as growth inhibitors.
142143
Similar heparitinase activity is also present in resident cells of the arterial wall, including smooth muscle cells 152 as well as blood-derived cells such as lymphocytes, 153 macrophages, 154 and neutrophils. 155 In fact, extravasation of blood cells into the arterial wall is correlated with level of heparitinase activity. The fact that lymphocytes, macrophages, and neutrophils are present in lesions of atherosclerosis 103 indicates a potential for the generation of proliferation-inhibitory proteoglycan fragments in vascular disease. Smooth muscle cells possess specific high-affinity receptors for heparirVheparan sulfate and can internalize this bound glycosaminoglycan. 145 These results raise the interesting possibility that heparin/heparan sulfate and heparin/heparan sulfate fragments may suppress the growth of smooth muscle cells at specific intracellular sites. Additional studies support this possibility. For example, HSPG is present on the hepatocyte cell surface as a phosphatidyiinositol-linked proteoglycan. 156 This HSPG is metabolically processed on the cell surface with the loss of the diacylglycerol portion of the phosphatidylinositol and is internalized by receptor-mediated endocytosis. A part of the HSPG is then processed in a nonlysosomal compartment of the cell, and selected fragments of heparan sulfate chains containing an unusual sulfated glucuronic acid appear in the nucleus without the core protein. 157 ' 158 Changes in the structures and amounts of the nuclear heparan sulfate are accompanied by changes in the growth behavior of hepatocytes. 156157158 Such studies indicate that the intemalization of HSPG by a cell may, in part, regulate the growth of that cell.
Thus, evidence continues to accumulate that some forms of HSPG act as growth modulators, yet the precise mechanism(s) is still not known. A number of studies have shown that heparin alters the secretory phenotype of cultured arterial smooth muscle cells.
138159 - 164 For example, heparin induces the synthesis of a 60 000 molecular weight collagen-like protein at 18 to 24 hours after the addition of the heparin molecule. 160 Other proteins of lower molecular weight (i.e., 35, 37,39 kd), believed to be apolipoprotein (apo) E containing proteins, 165 are induced within 4 to 8 hours of heparin exposure.
161162 - 163 No direct correlation between heparin regulation of these proteins and growth inhibition has been established, but it is noteworthy that these synthetic changes occur at dosages that are normally growth-inhibitory.
A recent finding that heparin decreases thrombospondin concentration in the extracellular matrix of cultured arterial smooth muscle cells is of interest because antibodies to thrombospondin were found to inhibit DNA synthesis in these cells. 186 In addition, thrombospondin and the mitogen epidermal growth factor (EGF) act synergistically to stimulate DNA synthesis by smooth muscle cells, and this effect is inhibited by heparin. 138164 Thus, it may be that certain components of the extracellular matrix are necessary for cellular proliferation 167 and that other matrix components, such as proteoglycans, influence the availability of such molecules. The fact that cellassociated HSPG can serve as a receptor for thrombospondin 168 supports this possibility. It is also possible that heparin-like molecules regulate growth by interfering with the response to specific mitogens. For example, heparin reduces the number of EGF receptors on smooth muscle cells.
38 Thus, the effect of heparin on growth may be due to a combination of effects on the matrix surrounding the cells and on the mitogenic machinery of the cell itself. Heparin also is effective in reducing smooth muscle cell proliferation in vivo after arterial injury and is thus capable of counteracting the effects of local and blood borne growth factors. 169 Associated with this cessation of growth is an increase in the concentration of proteoglycans in injured arteries. 170 In vitro studies have also shown that arterial smooth muscle cell cultures accumulate more proteoglycan in the presence of heparin. 171 The nature of this modulation is currently under study. The reader is also referred to a recent review that discusses heparin's effect on other arterial processes. 172 Although most of the evidence indicates that the ability of heparin and heparan sulfate to inhibit growth is not caused by their interaction with peptide growth factors to inactivate them, a variety of peptide growth factors with mitogenic activity toward smooth muscle cells, fibroblasts, and endothelial cells display heparin binding affinity. 172 -182 Endothelial cell growth factor (ECGF) is a polypeptide mitogen that has been purified and characterized from bovine neural tissue. This mitogen supports the proliferation and serial propagation of human endothelial cells in vitro. 174175176 Heparin binds to ECGF and potentiates the mitogenic activity of this polypeptide. The effectiveness of the interaction with heparin correlates with the ability of the mitogen to stimulate endothelial cell proliferation. 174 Heparin also releases ECGF from the surface of cultured endothelial cells. 177 Although the mechanism of heparin action is unclear, the synergistic activity suggests struc-tural interactions between the carbohydrate and mitogen. It is possible that heparin potentiates the activity of ECGF by causing the mitogen to assume a conformation with increased affinity for its receptor. 175 Likewise, it is possible that the receptor requires a heparin-ECGF complex for an "ideal fit." Heparin also exhibits affinity for other growth factors such as platelet-derived growth factor, 178 insulinlike growth factor, 179 and fibroblast growth factor.
190181182
Such interactions may effectively compartmentalize and retain growth factors for maximal activity. For example, Vlodavsky and colleagues have shown that heparinbinding FGF-like growth factors, which are angiogenic, are sequestered in the extracellular matrix by virtue of their binding to HSPG. 181182 Destruction of the heparan sulfate chains by hepannase efficiently releases the growth factor from the extracellular matrix of basement membranes. 182 Similar sequestration of growth factors by proteoglycan has also been observed in bone marrow. 183184 Collectively, these studies indicate that the glycosaminoglycan heparin, which is derived from mast cells, is capable of potentiating the action of growth factors in vitro. The presence of mast cells at the leading edge of developing blood vessels and the fact that heparin stimulates the growth of endothelial cells in vitro and angiogenesis in vivo suggests that mast cell heparin is important in modulating vascular cell behavior in vivo.
186186 Consistent with this suggestion is the observation that mast cell granules containing heparin can be internalized and degraded by endothelial cells 187 and can cause proliferation of microvascular endothelial cells. 188 It also may be that heparin-like molecules in the form of HSPG synthesized by endothelial or smooth muscle cells are effective in binding and potentiating the action of these different mitogens as suggested by the studies cited above. As discussed earlier, the HS chains in HSPG have some structural features in common with heparin derived from mast cells. In fact, a recent study demonstrates heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. 189 Anticoagulant HS has been isolated from vascular tissue that was shown to be free of mast cells. 38 However, Imamura and Mitsui 190 recently demonstrated that heparan sulfate and heparin exhibited opposing activities on the growth of human umbilical vein endothelial cells in the presence of acidic and basic FGF. Such results illustrate that the two molecules may differ in their activities associated with growth.
Proteoglycans also may act as receptors for growth regulatory substances. For example, Fransson etal. have shown that the core protein of a cell surface HSPG in fibroblasts binds transferrin and appears to have a structure nearly identical to the transferrin receptor. In addition, thrombospondin binds to the surface of vascular endothelial cells in a receptor-like fashion and this binding is inhibited by heparin, suggesting that thrombospondin associates with the surface of endothelial cells in a HSPG-dependent manner. 168 The importance of thrombospondin in regulating smooth muscle cell growth 164186 suggests a growth regulatory role for the HSPG present on the surface of smooth muscle cells. It remains to be determined whether thrombospondin associates with the surface of smooth muscle cells as it does with endothelial cells. Majack et al. 166 made the interesting suggestion that surface thrombospondin, presumably bound to a membrane form of HSPG, interact with certain proteases to facilitate the matrix degradation and remodeling that accompanies cell proliferation. Heparin, which inhibits SMC proliferation, also releases thrombospondin from the cell surface. Such loss of thrombospondin may result in dissociation of the protease from the cell surface and loss of the capacity of matrix degradation to permit cell division. Such speculation awaits proof.
Recent studies have shown that the high molecular weight receptor for transforming growth factor beta (TGF/3) (a multifunctional protein that influences growth and connective tissue synthesis in a wide variety of cells) is a proteoglycan containing heparan sulfate and CS chains. 183 These studies illustrate that cell surface-associated proteoglycans may play critical roles in the regulation of cell growth and differentiation.
Modulation of Proteoglycan Metabolism
A number of other factors are capable of modulating proteoglycan metabolism by vascular cells in the absence of cell proliferation and migration. For example, TGF/3, a platelet product, stimulates CSPG synthesis by human arterial smooth muscle cells without the stimulation of cell proliferation. 194 This effect is cell-specific in that this platelet product had no effect on proteoglycan synthesis by vascular endothelial cells. The type of extracellular matrix surrounding vascular cells also influences the metabolism of proteoglycans. For example, when arterial smooth muscle cells are cultured on hydrated collagen gels (type I collagen), they decrease their overall proteoglycan accumulation (expressed on a per cell basis) but increase the amount of iduronic acid-rich dermatan sulfate present in the extracellular matrix ( Figure 6C ). 91 Pulsechase studies indicate that the accumulation of this specific proteoglycan within the cell layer is due partly to decreased turnover and partly to increased synthesis. Other extracellular factors shown to influence proteoglycan synthesis by cultured vascular cells include oxygen, 195196 prostaglandins, 197 and lipids. 198199200 These studies indicate that a variety of factors are capable of influencing proteoglycan metabolism by vascular cells.
Hemostasls
Endothelial cells provide a nonthrombogenic lining for the vascular system by secreting or sequestering factors involved in maintaining blood fluidity such as plasminogen activators, 201 prostacyclin, 202 and thrombomodulin. 203 In addition, endothelial cells synthesize and secrete heparin-like HSPGs that bind to antithrombin III and enhance the inactivation of thrombin, inhibiting the clotting cascade. 1936 .
3738204
Heparin and heparan sulfate are related molecules that are part of a large family of heterogeneous proteoglycans. 205 ' 206 Heparin is distinguished from heparan sulfate in that it is more highly charged, appears to occur entirely in mast cells, and is an effective anticoagulant. However, heparin has many structural features in com-mon with heparan sulfates. Both mast cell heparins and HSPGs contain anticoagulant and nonanticoagulant species.
363738189 - 204 Generally, heparin contains more N-and O-sulfate and more iduronic acid but less N-acetyl and glucuronic acid than do HSPGs. Heparan sulfates, on the other hand, have a more ubiquitous animal and tissue distribution. Refer to Hovingh et al. 206 for a discussion of the relationship between these two sets of molecules.
The binding of heparin and heparan sulfate to antithrombin III occurs at lysyl residues in the antithrombin molecule and is thought to involve a specific molecular domain composed of the tetrasaccharide sequence: IdA (GIcA)-GlcNAc-6-O-SCV-GIcA-GlcN-SO 3 -3-O-SO 3 , which is absent in nonanticoagulant heparin or heparan sulfate (for reviews, see references 38 and 205). This binding is responsible for a 1000-fold acceleration of enzymeinhibitor complex formation. It is of interest that other purified hemostatic enzymes of the intrinsic coagulation cascade, i.e., factors IXa, Xa, Xla, and Xlla, also are neutralized by antithrombin III in a similar heparindependent way. However, heparin induces only a 4-to 15-fold enhancement in the rate of neutralization of these factors by antithrombin III. 38 Recent studies indicate that a very small percentage of the total HSPG synthesized by aortic and microvascular endothelial cells ( -1 % and 10%, respectively) accounts for the majority of antithrombin III binding 19 and anticoagulant activity. This HSPG binds to hydrophobic resins consistent with a membrane location and contains heparan sulfate chains that are enriched in the antithrombin III binding disaccharide sequence of GIcA-GlnNAc-SO 3 -3-O-SO 3 . These findings also demonstrate that molecules synthesized by cells other than mast cells possess anticoagulant properties.
It appears that endothelial surface proteoglycans are capable of binding not only anticoagulant factors but also procoagulant factors. 207208 For example, thrombin binds to the surface of cultured porcine aortic endothelial cells in a rapid and reversible manner and this binding is partially inhibited by pretreatment of the cells with purified heparitinase, 207 an enzyme that cleaves heparan sulfate chains. Thus, it may be that the inactivation of thrombin by antithrombin III is regulated, at least in part, by one or more HSPGs present at the surface of the endothelial cell and that bind both coagulant and anticoagulant factors.
The role of platelets in hemostasis, thrombosis, and atherosclerosis is well established.
103209 - 210 Less clear is what specific role(s) platelet secretory products play in arterial wall metabolism. For example, platelets contain a variety of substances that are stored in alpha granules and released when platelets are stimulated to aggregate in tissue injury, promoting coagulation at the damaged site. 210 Among these substances are a number of antjheparin factors such as platelet factor 4 (PF4), which binds to heparin and neutralizes heparin activity. 210 PF4 occurs complexed to a chondroitin sulfate proteoglycan, 211 which appears to function as a carrier molecule. More recent studies indicate that megakaryocytes synthesize at least two forms of CSPG and these forms, which are present within a granules of platelets, are released in response to thrombin. 212 The significance of the PF4:PG complex in arterial wall metabolism needs to be elucidated. The fact that heparin releases PF4 into the circulation similar to the release of lipoprotein lipase 213 suggests that PF4 also binds to a heparin-like molecule on the endothelial cell surface. In fact, additional studies demonstrate that PF4 binds to the surface of cultured human umbilical vein endothelial cells in a timedependent, saturable fashion and that heparin and HS compete for binding. 214 
Lipid Metabolism
Endothelial cell surface HSPGs also are involved in lipid metabolism. For example, lipoprotein lipase [adimeric enzyme responsible for the hydrolysis of di-and triacyiglycerol constituents of plasma very low density lipoproteins (VLDL) and chylomicrons] interacts with the surface of endothelial cells in a heparin/heparan sulfatedependent fashion.
215 -216 - 217 Recently, Klinger et al. 218 used a lipoprotein lipase-agarose affinity column to isolate an HSPG from a mixture of proteoglycans in rat brain and found it to be a membrane-associated proteoglycan of approximately 220 kd containing glycosaminoglycan chains of M r =14 000 to 15 000. The mechanism by which this proteoglycan interacts with the enzyme is not clear, but most probably involves the glycosaminoglycan portion of the molecule, since glycosaminoglycan chain length and the number of N-sulfate and N-acetyl groups on the glycosaminoglycan chain affect affinity for lipoprotein lipase. 219 -220 Another way in which endothelial cell-derived proteoglycan may modulate lipid metabolism is by modifying the charge density of the lipid as it passes through the endothelial barrier. The ability of cultured endothelial cells to bind, transport, and degrade low density lipoproteins (LDL) is well documented. 221 Further studies indicate that LDL can be modified by endothelial cells so that It becomes more negatively charged, allowing recognition by the modified LDL receptor of the macrophage. 222 It may be that endothelial-derived proteoglycans bind to LDL, and in turn, induce such a modification.
It is clear that regions of blood vessels that accumulate proteoglycans have a high propensity to accumulate lipid. For example, studies using the balloon injury model of experimental atherosclerosis indicate that proteoglycans accumulate within regions of injured vessels characterized by endothelial regrowth and not within regions devoid of endothelium 6 -7 . 223 -224 ( Figure 9 ). These studies also indicate that if animals are put on a high-fat diet, lipid accumulates in the re-endothelialized intima, the region characterized by excessive proteoglycan accumulation and not in the de-endothelialized portion 225226 ( Figure 9 ). Such studies raise the interesting possibility that during healing, the regenerating endothelium contributes to the proteoglycan composition of the arterial wall and in some way influences the metabolism of proteoglycans and lipids present in this region of blood vessel.
A number of studies now demonstrate that regions of vessels that have re-endothelialized have higher rates of proteoglycan synthesis and deposition than do deendothelialized vessels. 227 . Correlation of lipid and proteoglycan concentration in de-endothelialized and re-endothelialized aortas in rabbits on normal and lipid-rich diets. Note that the re-endothelialized unstained (white) regions contained the greatest concentration of proteoglycan (PG) and lipid in the fat-fed animals when compared to the de-endothelialized, Evans blue-stained (blue) regions. The finding that the white regions contained significantly more PG than the blue regions in animals on regular diets suggests that this increase in PG may predispose the white region to lipid accumulation.
with endothelial and smooth muscle cells indicate that endothelial cells are capable of stimulating proteoglycan synthesis by smooth muscle cells. 230 - 231 These findings suggest that endothelial cells may affect arterial proteoglycan content by: 1) increasing their own proteoglycan synthetic activity or that of adjacent smooth muscle cells, and/or 2) acting as a reverse barrier preventing loss or turnover of proteoglycan. A potential consequence of proteoglycan accumulation in blood vessels is the buildup of lipid (see reference 4 for a review). A number of articles refer to the isolation of PG-LDL complexes from normal and atherosclerotic arteries. Such complexes contain LDL, VLDL, and calcium, and morphologic evidence indicates that these complexes are highly aggregated. Recent work suggests that multiple pools of LDL-PG complexes may be present within blood vessels. 232233 For example, complexes extracted with saline contained chondroitin-6-sulfate as the major and hyaluronic acid as the minor glycosaminoglycan and were cholesterol ester-enriched. On the other hand, LDL-PG complexes isolated after collagenase treatment contained mostly hyaluronic acid and minor amounts of chondroitJn-6-sulfate. Complexes isolated after elastase contained only hyaluronic acid and were cholesterol ester-poor. These findings suggest that particular LDL-PG complexes may occur within different regions of the extracellular matrix within blood vessels.
Camejo and his colleagues 4 ' 234 -235236 have been studying the interaction of arterial proteoglycan with lipoprotein and have found that arterial CSPG exhibits a marked affinity for LDL and that this interaction may be dependent not only on the type of proteoglycan but also on the surface charge of the LDL. For example, a recent study has shown that a specific sequence enriched in positively charged amino acids in the apo B moiety of LDL effectively binds to proteoglycans. 238 These binding domains are part of the protein that interacts with LDL receptor. Thus, interaction of the proteoglycan with LDL may affect recognition of LDL by its surface receptor. In addition to CSPG, the small arterial DSPG also is capable of forming insoluble complexes with LDL in the presence of calcium, 237 while those proteoglycans containing HS exhibit only minimal lipoprotein binding activities.
18 - 237 -240 Intact proteoglycan is much more effective in precipitating LDL and VLDL than are isolated glycosaminoglycan chains.
238239 - 240 Removal of the protein core after -elimination or protease treatment of the proteoglycan abolishes its insoluble complex-forming ability. The role of net negative charge in complex formation is emphasized by the observation that desulfation of the proteoglycan drastically reduces its ability to interact with LDL 238 Thus, it appears that PG-lipoprotein formation involves a complex series of multiple interactions of protein-protein and proteincarbohydrate. It also is possible that lipids influence the proteoglycan content of the vascular wall and, in turn, influence lipid deposition. Hoff and Wagner 241 demonstrated that after 11 weeks on a hypercholesterolemic diet, porcine aortic glycosaminoglycan concentrations did not differ from that of normocholesterolemic animals, even though lipoproteins accumulated within the aorta. However, the relative amounts of aortic chondroitin sulfate increased, and dermatan sulfate decreased in the hypercholesterolemic animals, indicating that cholesterol feeding may influence the types of proteoglycans that accumulate but not the total quantity. Intense immunostaining using an antj-aortjc CSPG antiserum, has been observed in atherosclerotic lesions in the rabbit after lipkJ feeding 15 ( Figure 3 ). The mechanism responsible for this specific accumulation is unclear, but it may be that lipoproteins influence the synthesis of proteoglycans by the resident cells of the arterial wall. LDL increase the synthesis of proteoglycans by cultured bovine smooth muscle cells, but it is unclear whether specific types of proteoglycans synthesized are affected. The above studies demonstrate that proteoglycans within the extracellular matrix of blood vessels are capable of binding lipoproteins. However, lipid and lipoprotein are found not only within the extracellular matrix, but also within cells of the arterial wall during the genesis of the atherosclerotic lesion. Two cell types that are known to accumulate lipid in developing atherosclerotic lesions are smooth muscle cells and macrophages, 103 and recent studies suggest that proteoglycans may play a role in intracellular lipid accumulation in these cells as well. For example, it is known that macrophages contain few receptors for LDL, and LDL will not accumulate within macrophages when these cells are incubated with high concentrations of LDL. 242 However, if LDL is modified by acetylation, acetoacylation, or malondialdehyde derivation, macrophages dramatically increase their uptake of modified LDL. Enhancement of LDL uptake also occurs when macrophages are incubated with medium containing dextran sulfate. 243 These findings suggest that charge alteration of LDL molecules influences their recognition by macrophages. Thus, overall charge density of lipoproteins could be affected by complexing with negatively charged proteoglycans. Falcone et al. 244 demonstrated that insoluble complexes of LDL, heparin, fibronectin, and collagen were taken up more rapidly in combination and to a greater extent by macrophages than when these cells were incubated with LDL alone. Furthermore, this study demonstrated that catabolism of the endocytosed LDLcomplex was greatly diminished, causing cholesterol ester to accumulate within these cells. More recently, Hurt and Camejo 245 demonstrated that incubation of human LDL with human arterial CSPG increased LDL uptake by human monocyte-derived macrophages, indicating that proteoglycan alone is capable of modifying LDL. It is interesting that sulfated polyanions such as dextran sulfate inhibit the fusion of phagosomes with lysosomes within macrophages by modifying membrane fluidity of the lysosome. 246247 This finding may partially explain why LDL is not degraded and accumulates in macrophages, leading to foam cell formation. However, decreased degradation of LDL may not be the only mechanism by which lipid accumulates in macrophages. Salisbury et al. 248 demonstrated increased cholesterol ester synthesis when macrophages were incubated with aortic proteoglycan and plasma LDL. In addition, Vijayagopal et al. 249 showed that LDL complexed to aortic proteoglycan-hyaluronic acid aggregate was taken up by macrophages, but degraded more rapidly than LDL complexed to proteoglycan monomer. This enhanced degradation also was accompanied by increased cholesterol ester synthesis by the macrophage. This study also showed that acetyl-LDL completely inhibited the degradation of the LDL-PG complex, indicating that the complex may be recognized by the modified LDL receptor of the macrophage.
Atherosclerosis
Studies continue to demonstrate that proteoglycans accumulate within intimal lesions in both large and small vessels involved in atherosclerotic development. These increases appear to involve mainly the CSPG and DSPG families, while some studies indicate little change or even a decrease in HSPG with advancing atherosclerosis (for reviews see references 3, 4, 5, and 250 to 253). Little is known about whether the structural properties of intact proteoglycans are altered in developing atherosclerotic plaques. Wagner et al. 8 4 2 5 4 noted that CSPG isolated from human fatty-fibrous plaques exhibited less tendency to form aggregates with hyaluronic acid and that the aggregates present in fatty-fibrous arterial plaques were smaller than those present in normal aorta. Altered aggregate formation may have some bearing on arterial calcification (a complication of advanced atherosclerotic plaques) since the degree of proteoglycan aggregation is thought to influence calcification. 255 In addition, the CSPG isolated from human arterial lesions tends to be of larger hydrodynamic size, suggesting either that the synthesis or degradation of this monomer is altered or that it is complexed to other components in arterial lesions. Other minor changes in the structure of arterial proteoglycan have been noted. For example, DSPGs isolated from atherosclerosis-susceptible pigeons contain glycosaminoglycans that are smaller than similar chains isolated from aortic DSPGs of pigeons that are less susceptible to this disease. 96 Whether these differences influence the functional properties of arterial proteoglycans and whether other differences exist must await further investigation.
Conclusion
This review has concentrated on the role that proteoglycans play in vascular wall biology. As summarized in Figure 10 , there are a number of ways in which proteoglycans can influence the behavior of vascular cells and, in turn, the normal and pathophysiological properties of blood vessels. Clearly, these macromolecules are of enormous importance in maintaining the vicoelastjc state of the vessels, and any change in proteoglycan structure, content, or concentration will severely effect the biophysical properties of the tissue. We now know that a number of factors contribute to alteration of the proteoglycan content of the vascular wall through processes common to both normal development and disease, such as cell proliferation and migration, hormonal stimulation, and multiple ligand interactions. Such "alterations" may, in turn, generate conditions in which different proteoglycans acquire the capacity to "instruct" or to serve as important "informational transducers" regulating key events in vascular wall biology. The future of research in the cell biology of arterial proteoglycans is, indeed, challenging. It represents a critical component in the effort to understand those factors that contribute to cardiovascular disease-the leading cause of death in the United States and Europe. 
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